Stock Comparison

JNJ vs NVO

Johnson & Johnson vs Novo Nordisk A/S

The Verdict

NVO takes this one.

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Winner

NVO

Novo Nordisk A/S

1.3

out of 10

Distressed

Head-to-Head

$557.1B

Market Cap

$1.3T

26.5

P/E Ratio

10.6

21.8%

Profit Margin

37.2%

26.3%

Return on Equity

66.4%

0.6

Debt-to-Equity

0.7

Conservative

Overall Risk

Moderate

1.0

DVR Score

1.3

The Deep Dive

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

NVO1.3/10

Novo Nordisk (NVO) is a pharmaceutical powerhouse, commanding leadership in the diabetes and obesity markets, fueled by its dominant GLP-1 franchise. The Q1 2026 results show strong reported sales growth of 32% YoY at CER, and the company raised its 2026 outlook, reflecting robust demand. However, a critical red flag for 10x growth potential is the explicit *4% decline in adjusted sales due to low...

Full NVO Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.